归属于上市公司股东的净利润、归属于上市公司股东的扣除非经常性损益的净利润、基本每股收益、稀释每股收益、扣除非经常性损益后的基本每股收益较上年同期亏损减少，研发投入占营业收入的比例较上年同期减少，主要系商业化药品的销售收入与上年同期相比有所增长，同时随着公司核心产品拓益的多项临床试验达到主要研究终点以及“提质增效重回报”行动方案的实施，公司将资源聚焦于更具潜力的研发项目，临床、技术服务费及职工薪酬均相应减少，导致亏损减少。Junshi Bio (688180.SH) disclosed its semi-annual report for 2024, reporting that the company achieved revenue of 7.86 billion yuan during the reporting period...
According to the report released by Junshi Bio (688180.SH) on its semi-annual report for 2024, the company achieved revenue of 786 million yuan in the reporting period, with a year-on-year growth of 17.37%...
The revenue increased by approximately 116 million yuan, a year-on-year growth of 17.37%, mainly due to the increase in sales revenue of commercialized pharmaceuticals compared to the same period last year...
The net profit attributable to shareholders of the listed company, the net profit attributable to shareholders of the listed company excluding non-recurring gains and losses, basic earnings per share, diluted earnings per share, and basic earnings per share after deducting non-recurring gains and losses have decreased from the same period last year. The proportion of research and development investment in operating income has decreased compared to the same period last year...
